On May 7, 2025, Theriva Biologics, Inc. announced positive results from its VIRAGE Phase 2b trial, showing that patients treated with its product VCN-01 plus standard chemotherapy had a median overall survival of 10.8 months compared to 8.6 months with standard treatment alone. The trials indicate promising improvements in survival rates for patients with metastatic pancreatic cancer.